 Joel Marrs
Concepts (184)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 7 | 2022 | 444 | 1.410 |
Why?
| | Antihypertensive Agents | 5 | 2021 | 521 | 1.350 |
Why?
| | Hypertension | 7 | 2021 | 1276 | 1.260 |
Why?
| | Pharmacists | 8 | 2023 | 258 | 1.240 |
Why?
| | Hypolipidemic Agents | 5 | 2026 | 89 | 1.080 |
Why?
| | Dyslipidemias | 6 | 2026 | 184 | 1.070 |
Why?
| | Aspirin | 3 | 2015 | 406 | 1.020 |
Why?
| | Text Messaging | 3 | 2025 | 182 | 0.970 |
Why?
| | Platelet Aggregation Inhibitors | 3 | 2015 | 499 | 0.960 |
Why?
| | Cardiovascular Diseases | 10 | 2026 | 2191 | 0.950 |
Why?
| | Education, Pharmacy | 6 | 2023 | 120 | 0.870 |
Why?
| | Diabetes Mellitus, Type 2 | 7 | 2017 | 2602 | 0.740 |
Why?
| | Anticoagulants | 2 | 2019 | 748 | 0.710 |
Why?
| | Thiophenes | 2 | 2015 | 117 | 0.680 |
Why?
| | Atrial Fibrillation | 2 | 2019 | 558 | 0.670 |
Why?
| | Allylamine | 2 | 2012 | 6 | 0.660 |
Why?
| | Stroke | 4 | 2019 | 1271 | 0.650 |
Why?
| | Internship, Nonmedical | 2 | 2010 | 10 | 0.560 |
Why?
| | Cardiovascular Agents | 3 | 2026 | 166 | 0.560 |
Why?
| | Medication Reconciliation | 1 | 2018 | 32 | 0.530 |
Why?
| | Practice Guidelines as Topic | 6 | 2026 | 1582 | 0.460 |
Why?
| | Pharmaceutical Services | 2 | 2020 | 76 | 0.440 |
Why?
| | Cholesterol, LDL | 5 | 2019 | 360 | 0.440 |
Why?
| | Heart Failure, Diastolic | 1 | 2015 | 23 | 0.440 |
Why?
| | Kidney Failure, Chronic | 2 | 2011 | 599 | 0.430 |
Why?
| | Ticlopidine | 1 | 2015 | 52 | 0.430 |
Why?
| | Drug-Eluting Stents | 1 | 2015 | 88 | 0.420 |
Why?
| | Thromboembolism | 1 | 2015 | 129 | 0.420 |
Why?
| | Medically Underserved Area | 1 | 2015 | 100 | 0.410 |
Why?
| | Reminder Systems | 2 | 2025 | 140 | 0.380 |
Why?
| | Cardiology | 2 | 2026 | 362 | 0.370 |
Why?
| | Blood Pressure | 3 | 2016 | 1782 | 0.370 |
Why?
| | Piperazines | 1 | 2015 | 375 | 0.360 |
Why?
| | Hypoglycemic Agents | 2 | 2012 | 1399 | 0.360 |
Why?
| | Guideline Adherence | 1 | 2016 | 587 | 0.360 |
Why?
| | Glucosides | 1 | 2012 | 56 | 0.350 |
Why?
| | Urban Population | 1 | 2015 | 494 | 0.350 |
Why?
| | Patient Discharge | 2 | 2018 | 995 | 0.350 |
Why?
| | Humans | 48 | 2026 | 145763 | 0.340 |
Why?
| | Anticholesteremic Agents | 2 | 2012 | 155 | 0.330 |
Why?
| | Venous Thromboembolism | 1 | 2015 | 328 | 0.330 |
Why?
| | Thrombosis | 1 | 2015 | 400 | 0.330 |
Why?
| | Spironolactone | 1 | 2010 | 40 | 0.320 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2010 | 69 | 0.310 |
Why?
| | Preceptorship | 1 | 2010 | 63 | 0.290 |
Why?
| | Administration, Oral | 3 | 2019 | 867 | 0.290 |
Why?
| | Professional Role | 3 | 2020 | 170 | 0.280 |
Why?
| | Students, Pharmacy | 1 | 2010 | 96 | 0.280 |
Why?
| | Medication Therapy Management | 2 | 2020 | 72 | 0.280 |
Why?
| | Schools, Pharmacy | 3 | 2021 | 48 | 0.260 |
Why?
| | Drug Therapy, Combination | 4 | 2016 | 1043 | 0.260 |
Why?
| | Medication Adherence | 3 | 2025 | 540 | 0.260 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 3 | 2021 | 229 | 0.250 |
Why?
| | Benzodiazepines | 1 | 2008 | 168 | 0.250 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2007 | 46 | 0.250 |
Why?
| | Family Practice | 2 | 2010 | 407 | 0.250 |
Why?
| | Angiotensin Receptor Antagonists | 2 | 2021 | 115 | 0.240 |
Why?
| | Insurance Coverage | 1 | 2008 | 244 | 0.240 |
Why?
| | Renal Dialysis | 1 | 2010 | 466 | 0.240 |
Why?
| | Hypnotics and Sedatives | 1 | 2008 | 222 | 0.230 |
Why?
| | Certification | 3 | 2013 | 119 | 0.230 |
Why?
| | Deprescriptions | 1 | 2026 | 37 | 0.230 |
Why?
| | Sleep Initiation and Maintenance Disorders | 1 | 2008 | 196 | 0.220 |
Why?
| | Polypharmacy | 1 | 2026 | 94 | 0.220 |
Why?
| | Hospitalization | 2 | 2015 | 2460 | 0.220 |
Why?
| | Aged | 11 | 2025 | 26215 | 0.210 |
Why?
| | Heart Failure | 1 | 2018 | 2326 | 0.210 |
Why?
| | Faculty | 2 | 2017 | 148 | 0.210 |
Why?
| | Poverty | 1 | 2008 | 529 | 0.210 |
Why?
| | Endocrinology | 1 | 2025 | 77 | 0.200 |
Why?
| | Specialization | 3 | 2013 | 137 | 0.190 |
Why?
| | Social Identification | 1 | 2023 | 71 | 0.180 |
Why?
| | Ambulatory Care | 1 | 2007 | 610 | 0.180 |
Why?
| | Pharmacy | 1 | 2021 | 32 | 0.170 |
Why?
| | Middle Aged | 11 | 2025 | 36302 | 0.170 |
Why?
| | Colesevelam Hydrochloride | 2 | 2012 | 6 | 0.160 |
Why?
| | Pharmacy Service, Hospital | 2 | 2013 | 89 | 0.160 |
Why?
| | Cell Phone | 1 | 2021 | 82 | 0.160 |
Why?
| | American Heart Association | 3 | 2026 | 358 | 0.160 |
Why?
| | Secondary Prevention | 3 | 2016 | 251 | 0.150 |
Why?
| | Brain Ischemia | 2 | 2013 | 359 | 0.150 |
Why?
| | Diabetes Mellitus | 2 | 2020 | 1101 | 0.140 |
Why?
| | United States | 11 | 2026 | 16123 | 0.140 |
Why?
| | Societies, Pharmaceutical | 3 | 2021 | 14 | 0.140 |
Why?
| | Female | 13 | 2025 | 79035 | 0.140 |
Why?
| | Software | 1 | 2023 | 680 | 0.130 |
Why?
| | Age Factors | 2 | 2016 | 3346 | 0.130 |
Why?
| | Heart Valve Diseases | 1 | 2019 | 151 | 0.130 |
Why?
| | Retrospective Studies | 6 | 2021 | 17325 | 0.130 |
Why?
| | Colorado | 2 | 2023 | 4556 | 0.130 |
Why?
| | 4-Hydroxycoumarins | 1 | 2016 | 3 | 0.120 |
Why?
| | Blood Glucose | 3 | 2012 | 2344 | 0.120 |
Why?
| | Vitamin K | 1 | 2016 | 46 | 0.120 |
Why?
| | Dissociative Disorders | 1 | 2016 | 30 | 0.120 |
Why?
| | Community Participation | 1 | 2017 | 123 | 0.120 |
Why?
| | Cholesterol | 3 | 2019 | 408 | 0.120 |
Why?
| | Clinical Trials as Topic | 2 | 2012 | 1062 | 0.120 |
Why?
| | Male | 11 | 2025 | 73003 | 0.120 |
Why?
| | Primary Prevention | 2 | 2014 | 222 | 0.110 |
Why?
| | Risk Factors | 5 | 2019 | 10917 | 0.110 |
Why?
| | Patient Transfer | 1 | 2018 | 211 | 0.110 |
Why?
| | Aged, 80 and over | 4 | 2015 | 8346 | 0.110 |
Why?
| | Guidelines as Topic | 1 | 2016 | 268 | 0.100 |
Why?
| | Blood Coagulation Disorders | 1 | 2016 | 198 | 0.100 |
Why?
| | Diuretics | 2 | 2011 | 68 | 0.100 |
Why?
| | Adult | 8 | 2025 | 40872 | 0.100 |
Why?
| | Telemedicine | 1 | 2022 | 966 | 0.100 |
Why?
| | Emotional Intelligence | 2 | 2023 | 13 | 0.090 |
Why?
| | Suicide, Attempted | 1 | 2016 | 426 | 0.090 |
Why?
| | Follow-Up Studies | 3 | 2016 | 5428 | 0.090 |
Why?
| | Treatment Outcome | 2 | 2019 | 11793 | 0.090 |
Why?
| | Acute Disease | 1 | 2015 | 1036 | 0.090 |
Why?
| | Data Collection | 1 | 2014 | 643 | 0.090 |
Why?
| | Atherosclerosis | 1 | 2015 | 409 | 0.090 |
Why?
| | Benzhydryl Compounds | 1 | 2012 | 81 | 0.090 |
Why?
| | Hyperlipidemias | 1 | 2012 | 120 | 0.080 |
Why?
| | Health Promotion | 1 | 2017 | 775 | 0.080 |
Why?
| | Continuity of Patient Care | 1 | 2013 | 297 | 0.080 |
Why?
| | Universities | 1 | 2013 | 445 | 0.080 |
Why?
| | Sex Factors | 1 | 2016 | 2110 | 0.080 |
Why?
| | Drug Resistance | 1 | 2010 | 145 | 0.080 |
Why?
| | Interinstitutional Relations | 1 | 2010 | 56 | 0.080 |
Why?
| | Cross-Sectional Studies | 1 | 2021 | 5922 | 0.070 |
Why?
| | Pragmatic Clinical Trials as Topic | 2 | 2021 | 133 | 0.070 |
Why?
| | Myocardial Infarction | 1 | 2016 | 1211 | 0.070 |
Why?
| | Coronary Artery Disease | 1 | 2015 | 750 | 0.070 |
Why?
| | Pregnancy | 1 | 2021 | 7215 | 0.070 |
Why?
| | Advisory Committees | 2 | 2021 | 229 | 0.070 |
Why?
| | Patient-Centered Care | 1 | 2013 | 547 | 0.070 |
Why?
| | Dipeptidyl Peptidase 4 | 1 | 2007 | 15 | 0.060 |
Why?
| | Adamantane | 1 | 2007 | 18 | 0.060 |
Why?
| | Receptors, GABA-A | 1 | 2008 | 137 | 0.060 |
Why?
| | Emotions | 2 | 2023 | 577 | 0.060 |
Why?
| | Drug Monitoring | 1 | 2010 | 401 | 0.060 |
Why?
| | Eicosapentaenoic Acid | 1 | 2006 | 37 | 0.060 |
Why?
| | Hypertriglyceridemia | 1 | 2006 | 45 | 0.060 |
Why?
| | Pyrrolidines | 1 | 2007 | 125 | 0.060 |
Why?
| | Practice Patterns, Physicians' | 1 | 2015 | 1372 | 0.060 |
Why?
| | Docosahexaenoic Acids | 1 | 2006 | 88 | 0.060 |
Why?
| | Nitriles | 1 | 2007 | 211 | 0.060 |
Why?
| | Inappropriate Prescribing | 1 | 2026 | 66 | 0.060 |
Why?
| | Exercise | 1 | 2017 | 2205 | 0.060 |
Why?
| | Insurance, Health | 1 | 2008 | 311 | 0.060 |
Why?
| | Aging | 1 | 2016 | 1973 | 0.060 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2006 | 143 | 0.060 |
Why?
| | Risk Assessment | 2 | 2016 | 3752 | 0.060 |
Why?
| | Young Adult | 4 | 2015 | 14251 | 0.050 |
Why?
| | Hyperglycemia | 1 | 2009 | 379 | 0.050 |
Why?
| | Triglycerides | 1 | 2006 | 520 | 0.050 |
Why?
| | Patient Compliance | 1 | 2008 | 588 | 0.050 |
Why?
| | Enzyme Inhibitors | 1 | 2007 | 821 | 0.050 |
Why?
| | Animals | 3 | 2012 | 38097 | 0.050 |
Why?
| | Pandemics | 2 | 2022 | 1711 | 0.050 |
Why?
| | Adolescent | 4 | 2015 | 22573 | 0.050 |
Why?
| | Sleep | 1 | 2008 | 889 | 0.040 |
Why?
| | Curriculum | 1 | 2006 | 1074 | 0.040 |
Why?
| | Annual Reports as Topic | 1 | 2017 | 2 | 0.030 |
Why?
| | Lipids | 1 | 2022 | 707 | 0.030 |
Why?
| | Students | 1 | 2023 | 652 | 0.030 |
Why?
| | Organizational Policy | 1 | 2017 | 78 | 0.030 |
Why?
| | Health Personnel | 1 | 2021 | 757 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1751 | 0.030 |
Why?
| | Eating | 1 | 2016 | 387 | 0.030 |
Why?
| | Mechanical Thrombolysis | 1 | 2013 | 5 | 0.020 |
Why?
| | Telephone | 1 | 2013 | 177 | 0.020 |
Why?
| | Clinical Competence | 2 | 2011 | 1247 | 0.020 |
Why?
| | Adrenergic Antagonists | 1 | 2011 | 5 | 0.020 |
Why?
| | Thrombolytic Therapy | 1 | 2013 | 164 | 0.020 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2011 | 38 | 0.020 |
Why?
| | Phytotherapy | 1 | 2011 | 74 | 0.020 |
Why?
| | Drug Utilization | 1 | 2011 | 168 | 0.020 |
Why?
| | Calcium Channel Blockers | 1 | 2011 | 166 | 0.020 |
Why?
| | Patient Care Management | 1 | 2010 | 56 | 0.020 |
Why?
| | Hospitals, University | 1 | 2010 | 176 | 0.020 |
Why?
| | Cohort Studies | 1 | 2020 | 6032 | 0.020 |
Why?
| | Governing Board | 1 | 2009 | 7 | 0.020 |
Why?
| | Prospective Studies | 1 | 2020 | 8075 | 0.020 |
Why?
| | Patient Readmission | 1 | 2013 | 772 | 0.020 |
Why?
| | Length of Stay | 1 | 2013 | 1350 | 0.020 |
Why?
| | Databases, Factual | 1 | 2013 | 1491 | 0.020 |
Why?
| | Inpatients | 1 | 2010 | 553 | 0.010 |
Why?
| | Prevalence | 1 | 2013 | 2874 | 0.010 |
Why?
| | Drug Combinations | 1 | 2006 | 396 | 0.010 |
Why?
| | Primary Health Care | 1 | 2015 | 1737 | 0.010 |
Why?
|
|
Marrs's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|